Patents by Inventor James Rusnak

James Rusnak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating cardiovascular disease using a soluble CTLA4 molecule
    Patent number: 7671022
    Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: March 2, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventor: James Rusnak
  • Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
    Publication number: 20100041602
    Abstract: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
    Type: Application
    Filed: November 19, 2008
    Publication date: February 18, 2010
    Inventors: David Hagerty, James Rusnak
  • Methods for treating cardiovascular disease using a soluble CTLA4 Molecule
    Publication number: 20090068203
    Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: August 14, 2007
    Publication date: March 12, 2009
    Inventor: James Rusnak
  • Methods for treating cardiovascular disease using a soluble CTLA4 molecule
    Publication number: 20090041790
    Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: October 19, 2007
    Publication date: February 12, 2009
    Inventor: James Rusnak
  • Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
    Patent number: 7482327
    Abstract: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: January 27, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Hagerty, James Rusnak
  • Methods for treating cardiovascular disease using a soluble CTLA4 molecule
    Patent number: 7307064
    Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: December 11, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventor: James Rusnak
  • Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
    Publication number: 20070009511
    Abstract: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
    Type: Application
    Filed: April 6, 2006
    Publication date: January 11, 2007
    Inventors: David Hagerty, James Rusnak
  • Methods for treating cardiovascular disease using a soluble CTLA4 molecule
    Publication number: 20050123539
    Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: August 3, 2004
    Publication date: June 9, 2005
    Inventor: James Rusnak